NCT07416409 2026-02-18
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Completed
Clinical Trials
7 trialsNCT04158258 2026-02-12
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Active not recruiting
NCT06961331 2026-01-09
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
Pfizer
Completed
NCT03199300 2025-12-11
InvestiCAT
University Medical Center Groningen
Active not recruiting
NCT06663787 2025-11-28
HER2 CR
Nagoya City University
Active not recruiting
NCT03738553 2025-10-29
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
University of Washington
Active not recruiting
NCT07009600 2025-06-06
Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
Samsung Medical Center
Completed